The aim of this study was to combine clinicopathologic variables associated with overall survival after gastric resection with D2 lymphadenectomy (D2 gastrectomy) for gastric cancer into a prediction nomogram.
INTRODUCTION
Gastric cancer still remains the second most common cause of cancer-related death and is responsible for approximately one million deaths annually. 1 In Korea, gastric cancer is the most prevalent cancer and the second leading cause of cancer-related death. 2 The only proven and potentially curative treatment for gastric cancer without distant metastasis is radical resection of the stomach combined with regional lymphadenectomy. Regarding D2 lymphadenectomy, a recently reported Dutch trial revealed that cancer-related death rates were lower in the D2 lymphadenectomy group. 3 In 2010, the seventh edition of the American Joint Committee on Cancer (AJCC) TNM classification was published, 4 and this system stratified M0 gastric cancer into seven risk groups according to the pathologic depth of invasion and the number of metastatic lymph nodes. However, other factors such as age, sex, size of the tumor, and differentiation could be considered for predicting individualized survival. Nomograms have been developed to quantify risk by combining prognostic factors in some diseases. [5] [6] [7] However, nomograms predicting survival of gastric cancer are few in number, and one reported nomogram was based on a Western database. 8 This nomogram has been validated for accuracy in the Western population. [9] [10] [11] In Korea, which has the highest incidence of gastric cancer in the world, 12 surgeons have accumulated substantial surgical experience, and gastric resection with D2 lymphadenectomy (D2 gastrectomy) is routinely performed with low morbidity and mortality rates. 13, 14 On the basis of this surgical practice and data collection, the gastric cancer data set of Seoul National University Hospital (SNUH) in Seoul, Korea was reflected in revising the AJCC TNM classification for gastric cancer. 15 The aim of the current study was to combine clinicopathologic variables that are associated with overall survival after D2 gastrectomy for gastric cancer into a prediction nomogram based on the data of a single large-volume institution. We also compared the discriminating value of the nomogram to that of the seventh AJCC TNM classification.
PATIENTS AND METHODS

Data Set
Between January 1, 1986, and December 31, 2007, among patients who underwent gastric cancer surgery at the Department of Surgery at SNUH, we collected data for 7,954 patients who satisfied the following inclusion criteria: the presence of primary gastric cancer; no combined malignancy; no preoperative chemotherapy; no distant metastasis; R0 resection (no residual macroscopic or microscopic tumor); more than 15 examined lymph nodes; and without one or more missing values.
This data set included patient demographics (age and sex), pathologic characteristics (location, size, gross type, histology, depth of invasion, number of metastatic lymph nodes, and number of examined lymph nodes), adjuvant chemotherapy, and follow-up data (follow-up duration and survival). The location of the tumor was categorized as upper third, middle third, or lower third by the center of the lesion. Adenocarcinoma of the esophagogastric junction within the stomach was categorized as upper third gastric cancer. 16 The size of the tumor was measured at the longest diameter. Gross type was categorized as early gastric cancer, advanced gastric cancer with Borrmann type I to III, or advanced gastric cancer with Borrmann type IV. The histologic subtype was categorized as differentiated type (papillary adenocarcinoma, well-differentiated tubular adenocarcinoma, and moderately differentiated tubular adenocarcinoma) or undifferentiated type (poorly differentiated tubular adenocarcinoma, signet ring cell carcinoma, and mucinous adenocarcinoma). The depth of invasion was categorized as mucosa, submucosa, proper muscle, subserosa, serosa, or adjacent organ invasion. The number of metastatic lymph nodes was categorized according to the node grouping of the seventh AJCC TNM classification (zero, one to two, three to six, seven to 15, or Ն 16 nodes). Adjuvant chemotherapy was categorized as received or not received. Follow-up data were collected from hospital records or the National Statistical Office data for patients who were lost to follow-up. The follow-up duration was measured from the time of surgery to the last follow-up date, and information regarding the survival status at the last follow-up was collected.
Construction of the Nomogram
For nomogram construction and validation, we randomly assigned two thirds of the patients to the training set (n ϭ 5,300) and one third to the validation set (n ϭ 2,654). The clinicopathologic characteristics of the training and validation sets were evaluated.
The proportional hazards (PH) assumption and linearity assumption in continuous variables (size, examined lymph nodes) were examined using restricted cubic splines. 17, 18 Continuous variables were transformed to adequate form for fitting the PH and linearity assumptions. For the categorical variables, a log-log survival plot was used for identifying the PH assumption, and all variables were fitted to the PH assumption. Variables were selected by the forward stepwise selection method in the Cox PH regression model. On the basis of the predictive model with the identified prognostic factors, a nomogram was constructed for predicting 5-and 10-year overall survival.
Validation of the Nomogram
Nomogram validation consisted of discrimination and calibration by using the validation set. Discrimination was evaluated using a concordance index, which provides the probability that for two randomly selected patients, when one patient has an event before the other, this patient has a poorer predicted outcome as determined by the nomogram. Harrell's C-index, which is appropriate for censored data, was used for evaluating the discrimination. 18, 19 In general, a C-index value greater than 0.75 is considered to represent relatively good discrimination. Calibration was performed by comparing the means of predicted survival with those of actual survival with observed Kaplan-Meier estimates after grouping of the nomogram predicted survival by decile.
The nomogram was validated by two validation sets. The first validation used the SNUH validation set (n ϭ 2,654) by data-splitting method because the SNUH has a large enough internal database, and the second validation was performed using a data set from one of the most active Japanese institutes, Cancer Institute Ariake Hospital (CIAH), which has a large prospective database. We collected the CIAH validation set (n ϭ 2,500), which satisfied the aforementioned inclusion criteria, and examined the clinicopathologic variables that were included in the nomogram.
Statistical significance was set as P Ͻ .05 in a two-tailed test. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC), SPSS version 19 (SPSS, Chicago, IL), and R software version 2.13.2 (http://www .r-project.org) with the design and survival packages. This study was approved by the Institutional Review Board of SNUH (H-1109-051-378).
RESULTS
The clinicopathologic characteristics for the training set (n ϭ 5,300) and SNUH validation set (n ϭ 2,654) are listed in Table 1 . The mean numbers of examined lymph nodes were 32.4 Ϯ 12.4 and 32.6 Ϯ 12.9 nodes in the training set and validation set, respectively. In the training set and validation set, 69.5% and 70.3% of patients, respectively, had more than 25 lymph nodes examined.
After examination and transformation of variables to fit in the Cox PH regression model, variables were selected by the forward stepwise selection method (P Ͻ .05). Table 2 lists the selected variables with hazard ratios. The hazard ratios were significantly higher for older age, male sex, location of upper part of stomach, advanced depth of invasion, increased number of metastatic lymph nodes, and decreased number of examined lymph nodes. However, size, histology, gross type, and adjuvant chemotherapy were not found to be significant. Figure 1 shows the nomogram predicting 5-and 10-year overall survival that was constructed based on selected variables with hazard ratios. The nomogram can assign the probability of survival by adding up the scores identified on the points scale for each variable. The total score projected to the bottom scale indicate the probability of 5-and 10-year survival.
Validation was performed by using the SNUH and CIAH validation sets. The clinicopathologic characteristics for the CIAH validation set (n ϭ 2,500) are listed in Table 1 . In the CIAH validation set, we examined clinicopathologic variables that were included in the nomogram.
In the SNUH validation set, Harrell's C-index was 0.78 (95% CI, 0.73 to 0.82). Figure 2 shows the calibration plot of the nomogram. The x-axis is the predicted survival calculated by the nomogram, and the y-axis is the actual survival estimated by the Kaplan-Meier method. The solid line represents the ideal reference line where predicted survival corresponds with the actual survival, and the dotted lines represent a 10% margin of error. The actual survival corresponded closely with the predicted survival and was always within the 10% margin of error. We compared the discrimination of the nomogram with that of the seventh AJCC TNM classification. Nomogram discrimination was 0.78 (95% CI, 0.73 to 0.82), which was superior to that of the seventh AJCC TNM classification (0.69; 95% CI, 0.64 to 0.074; P Ͻ .001). Figure 3 illustrates the 5-year survival predicted by the nomogram in each stage of the seventh AJCC TNM classification. A wide range of predicted survival could be identified in each TNM stage. Furthermore, the range of predicted survival was wider for higher stages.
In the CIAH validation set, Harrell's C-index was 0.79 (95% CI, 0.73 to 0.85). Figure 4 shows the calibration plot of the nomogram. Although the actual survival was slightly higher than the predicted survival, it was within a 10% margin of nomogram prediction.
DISCUSSION
This study is significant because a large cohort of patients who underwent D2 gastrectomy that was verified in revision of the AJCC TNM classification was used to develop the nomogram. There are statistical methods for internal validation such as cross-validation and bootstrap resampling; however, these methods have a theoretical probability of overinterpretation. 20 For this reason, external validation is essential for ensuring external applicability, although the predictive accuracy decreased in the external validation set. The most stringent external validation involves using a data set from other countries, whereas less stringent external validation involves using a data set from different institutions or a validation set by data-splitting method from the same institution. 18 In this study, we performed two kinds of external validation using a validation set that was independent from the training set in the same institution and a validation set from one of the most active Japanese institutes.
Compared with a previous nomogram based on a Western database, Lauren classification and size were excluded from this nomogram. In data collection, we did not include Lauren classification because missing data would have reduced the statistical power. In addition, Lauren classification was not significantly associated with survival in the multivariate analysis. 8 Another difference is that we used categorical variables for age and the number of metastatic lymph nodes for clinical convenience. Although continuous variables can preserve information more than categorical variables, drawing lines to points in the nomogram and adding points can be ambiguous and cumbersome. For this study, we categorized the number of metastatic lymph nodes by using statistical methods. However, discrimination was not much better than the lymph node grouping using the seventh AJCC TNM classification (results not shown).
In this study, we categorized the tumor location as upper third, middle third, and lower third gastric cancer. Although the seventh AJCC TNM classification regards adenocarcinoma of the esophagogastric junction as esophageal cancer, our previous study showed that adenocarcinoma of the esophagogastric junction within the stomach should be considered as gastric cancer. 16 Compared with Kattan's nomogram, the proportion of upper third gastric cancer was much smaller in this study (49.5% v 12.4%, respectively). Nevertheless, upper third gastric cancer similarly contributed to the nomogram as an indicator of poor prognosis. As a result, when the TNM stage is the same between two cohorts, the survival can differ because of variables that are not considered in TNM classification. However, using this nomogram with significant clinicopathologic variables including age, location of the tumor, number of examined lymph nodes, and so on, we demonstrated that patient survival can be more precisely predicted than when using TNM stage. In fact, Figure 3 demonstrates that patients with the same TNM stage had diverse survival. For generalized use of the nomogram by other institutions or other regions, it is important to minimize the effect of differences in the surgical strategy and pathologic examination. In this study, we excluded patients when the number of examined lymph nodes was less than 16. The examination of at least 16 lymph nodes ensured the surgical quality of D2 lymphadenectomy and prevented stage migration effect. The sixth edition of the AJCC staging manual for gastric cancer recommends that at least 16 lymph nodes be examined for correct assessment of the lymph node status.
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Several studies have reported that the examination of more than 15 lymph nodes improves the prediction of prognosis in gastric cancer.
22,23 Kong et al 24 reported that the survival rate increased as the number of examined lymph nodes increased by the stage migration effect. In this study, the mean numbers of examined lymph nodes were 32.4 and 32.6 in the training and validation sets, respectively. The proportion of patients with more than 25 examined lymph nodes was approximately 70% in each group. This result represents the high relevance of D2 lymphadenectomy in this cohort compared with the Western study.
Regarding adjuvant chemotherapy in gastric cancer, there have been few randomized controlled trials, and no regimens have been established as the standard after gastrectomy with D2 lymphadenectomy before 2007. 25 Recently, adjuvant oral fluoropyrimidine (S-1) after gastrectomy with D2 lymph node dissection exhibited a survival benefit in a large-scale randomized controlled trial. 25, 26 Another phase III trial exhibited a benefit in 3-year disease-free survival after adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy compared with gastrectomy alone (74% v 59%, respectively; P Ͻ .001). 27 In this study, however, adjuvant chemotherapy failed to demonstrate significance in the Cox PH regression model and thus was excluded from the nomogram. In our institution, patients with stage II or III gastric cancer usually receive adjuvant chemotherapy with a relatively uniform protocol based on fluorouracil and platinum. Unlike randomized controlled trials for adjuvant chemotherapy, adjuvant chemotherapy was omitted only in patients with poor functional status and reluctant to receive chemotherapy. As a result, adjuvant chemotherapy is believed to have little significance as a variable in this study.
External validation in both the SNUH and CIAH validation sets demonstrated good discrimination power (Harrell's C-index, 0.78 and 0.79, respectively). Calibration using the SNUH validation set demonstrated that the actual survival corresponds closely with the predicted survival. In the CIAH validation set, the actual survival was slightly higher than the predicted survival, although it was within a 10% margin of nomogram prediction. The Japanese Gastric Cancer Association reported that the 5-year survival rate of patients with middle third gastric cancer was higher than that of patients with lower third gastric cancer (78.9% v 71.9%, respectively). 28 However, the score of middle third gastric cancer is higher than that of lower third gastric cancer in our nomogram. In addition, because the proportion of middle third gastric cancer was high (51.3%) in the CIAH validation set, the actual survival could be slightly higher than the predicted survival.
The present study has several limitations. First, patient comorbidity was not reflected in this nomogram. We expect that comorbidity will affect overall survival to some extent. However, because of the diversity of comorbidity, it is hard to create categorized variables and to quantify risk. According to a report of the National Statistical Office in Korea, in 2010, the most common cause of death in Korea was malignancy, and the next most common cause was cerebrovascular disease, which carried a 3.2-fold lower risk of death than cancer. 29 In this study, because patients with other malignancies were excluded from data collection, the impact of comorbidity on survival is expected to be minimal. Second, the time span for the data set is more than 20 years. A question might be raised about whether this nomogram can be applied to present patients. In our institution, however, overall strategies for D2 lymphadenectomy and pathologic examination have not changed during this period. Splenectomy was considered when the advanced gastric cancer was located at the upper third greater curvature side, and distal pancreatectomy was not routinely performed for D2 lymphadenectomy. Although, the overall survival was better in the later period, this was a result of the increased proportion of early gastric cancer diagnoses because of a nationwide screening program. 13 In summary, we developed and externally validated a nomogram predicting 5-and 10-year overall survival after D2 gastrectomy for gastric cancer based on an Eastern database. The nomogram provides significantly better discrimination than the seventh AJCC TNM classification and also provides an individualized prediction of survival. The accuracy was validated by large data sets from Korean and Japanese institutes. We believe that this nomogram can be useful in Korea and Japan, where the incidence of gastric cancer is high and D2 gastrectomy is routinely performed. For the generalized use of this nomogram, validation by a Western cohort is required.
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